were acidified on arrival at the laboratory. In all cases the volumes were measured and a small specimen stored at -20°C until analysed.
specimen stored at -20°C until analysed.
Samples were analysed for cystine and cysteinepenicillamine disulphide by means of a Technicon TSM automatic amino-acid analyser. Suitable volumes of the acidified urine samples, together with 25 nmol of norleucine internal standard were loaded onto the sampler cartridges. A 41.0 x 0.5 cm column of Technicon Chromobeads C3 resin maintained at 47°C was eluted with 0.3 M lithium citrate buffer pH 3.46 until the cystine and cysteine-penicillamine had eluted. The column was then eluted with a similar buffer pH 4.15 until norleucine appeared, after which the column was treated with 0.3 M lithium hydroxide solution and equilibrated with pH 3.46 buffer in readiness for the next sample. The whole process took 70 minutes for each sample. This accelerated amino-acid analyser programme was developed specifically for the present application.
Patients Patient 1 is a 26-year-old man who had a renal stone removed when he was 24 years old, and a nephrectomy done at the age of 25 years. He has been treated with D-penicillamine (750 mg at 2200 h) for about a year. There has been no evidence of stone recurrence. Patient 2 is a 15-year-old girl who presented with a cystine calculus impacted in the left pelviureteric junction. This was removed and the patient was treated with D-penicillamine. A rash developed after 10 days, the treatment was stopped and the patient desensitized to D-penicillamine under prednisolone cover. She has been treated with the present regime for 10 months without any recurrence of stones. Patient 3 is a 29-year-old man who has had repeated attacks of renal colic associated with the passage of cystine sand since he was 18 years old. He was treated for about eight months with N-acetyl-D-penicillamine when he was 20 years old.This treatment was stopped when he developed heavy proteinuria, and he was then treated with a high-fluid intake regime. This did not completely control the tendency to stone formation, and he has now been treated with the present regime for 22 months without stone formation or any adverse side-effects. Patient 4 is an 18-year-old woman who has been known to have cystinuria since she was 6 years old and had been treated with D-penicillamine in increasing doses since childhood. She has remained well and grown normally. The single dose D-penicillamine regime was begun four years ago and the dose has been in the range 450-
Introduction
The use of thiol reagents in the treatment of cystinuria has become well established since Dpenicillamine therapy was first described by Crawhall et al. (1963) . The basis of therapy lies in the formation of soluble mixed disulphides between the drug and cysteine which are excreted in the urine in place of the relatively insoluble cystine. This renders the urine unsaturated with respect to cystine and reduces the chance of urolithiasis, which is the only clinical manifestation of this inherited disorder of amino-acid transport. Alternative treatments have included (1) a high fluid intake to produce a marked diuresis throughout the 24 hours; (2) administration of oral sodium bicarbonate in large doses in order to maintain the urinary pH at relatively high levels at which cystine is more soluble; and (3) various dietary regimes, e.g. as described by Smith et al. (1959) . - The disadvantages of long-term therapy with penicillamine include certain adverse side-effects which are summarized by Crawhall & Watts (1968) , as well as the cost of prescribing and the inconvenience of taking gram quantities of the drug throughout the day. The hydration regime of Dent et al. (1965) has the disadvantage that the patient's sleep must be interrupted to drink more water and to pass urine during the night. If adequate diuresis is not maintained overnight, the solubility limit of cystine is very likely to be reached, with the risk of stone formation. This paper describes a treatment regime wherein a single moderate dose of D-penicillamine (not more than 750 mg of the free base) is given in the late evening, usually at 2200 h, and is coupled with adequate hydration during the day (two to three litres during the waking hours without necessarily an extra drink at bedtime) in an attempt to keep the urinary cystine concentration below the saturation level (1.6 mmol per litre at pH 7 and 370C) throughout the 24 hours (Dent & Senior 1955) , without encountering the complications described above.
Materials and methods
Six-hour urine collections were made, ending at 0200, 0800, 1400 and 2000 h during ward admissions of 5 patients. Urine was collected in bottles containing 5 ml of concentrated hydrochloric acid. In addition, fresh collections for the 750 mg at 2200 h. There has been no stone formation. Patient S is a 22-year-old woman who has taken D-penicillamine continuously since she was nine years old. She had recurrent stones in early childhood and a right nephrectomy to remove a shrunken, infected, functionless kidney when she was 10 years old. She has remained stone-free and has taken only a single night time dose (750 mg) of D-penicillamine for the past four years.
Results
The mean values for the 24-hour excretion of cystine before and during D-penicillamine treatment (750 mg D-penicillamine at 2200 h) are presented in Table 1 , and show that this dose of the drug had little effect on the total excretion of the amino acid. Table 2 summarizes the total half cystine (cystine plus the cysteine moiety of cysteine-penicillamine) excretion values during the same period; these were correspondingly little changed. However, the concentration of cystine in the urine collected during the period 0200-0800 h was significantly reduced by the present regime (Table 3 ). The results for patient 3 suggest that a larger dose of D-penicillamine or a larger fluid intake may be needed in this case.
The detailed changes in the excretion of cystine, cysteine-penicillamine, total half cystine and urine volumes during treatment are shown for patient 1 in Fig 1, which illustrates the shortterm effect of these single doses of D-penicil- before she was treated. The highest concentrations occur in the 0200-0800 h collections. The samples analysed during treatment were also collected between these times and show that the urine was no longer saturated with respect to cystine during the night.
Discussion
Adequate hydration reduces the concentration of urinary cystine below its saturating concentration in the urine. Most patients can achieve an adequate rate of urine flow for this purpose by day in temperate climates, but may find it impossible to do so consistently at night. Although the main adverse reactions to Dpenicillamine appear to have an immunological basis, this may not apply to them all, particularly those which stem from the lathyrogenic properties of D-penicillamine. It is desirable to lower the dose of the drug which is given on economic as well as on possible toxicological grounds. The present work shows that the dose of D-penicillamine need not exceed 750 mg daily provided that this is given as a single dose at about 2200 h and is accompanied by a moderately high intake of fluids during the daytime.
It has previously been recommended that sufficient penicillamine should be given in divided doses throughout the 24 h to keep the urinary cystine content below about 200 mg/g creatinine (=approximately 100 ,tmol cystine/mmol creatinine) or about 200 mg/litre (0.83 mmol/litre), the determinations being made on 24 h urine collections or on the most concentrated specimen of urine passed (Watts 1976) . Our present limited experience suggests that the regime which we now propose is suitable for the prevention of stone recurrence after nephrolithotomy or the spontaneous passage of a stone. However, until more experience has accumulated, we recommend that the previous criteria be adhered to when the object of treatment is to dissolve cystine stones in situ.
Summary
(1) A single dose of D-penicillamine (not more than 750 mg) taken at 2200 h, together with a prescribed fluid intake of two to three litres during the waking hours, without extra drinks at night, is sufficient to keep the concentration of the urinary cystine below the saturating concentration of urine throughout the 24 h period.
(2) This regime does not materially reduce the total 24 h excretion of cystine.
(3) The effect of D-penicillamine is mainly seen in the urine excreted between 0200 and 0800 h. (4) This regime is provisionally recommended for the prevention of cystine stone recurrence but not for stone dissolution. Larger total amounts of D-penicillamine given in divided doses are still recommended for the latter purpose. (Fig 1) in one cystinuric patient who is fairly typical of a considerable number of cystinurics whose daily individual urinary cystine concentrations I have measured. There is a wide range of urinary cystine levels, with significantly higher levels during the night. It is worth noticing that high concentrations can be achieved during the daytime period, exceeding the 1 mmol to 1.5 mmol/l levels at which urine is saturated. I think that daytime urines saturate more easily than night-time urines where there are solubilizing agents present.
One comment about the method I used for these measurements: although amino-acid analysis is normally used to deal with our analytical problems, but for this large number of urines we required an auto-analyser method to measure the cystine. I used a cyanide/acid ninhydrin reagent. The cyanide specifically breaks down cystine but not cysteine-penicillamine disulphide to cysteine (Boyde T R C 1968, Journal of the Chemical Society C, 2751), which can be detected with a specific acid ninhydrin reagent (Gaitonde M K, 1957, Biochemical Journal 104, 627) . It is not a method to be practised by the unskilled because hydrogen cyanide is liberated. It is potentially a hazardous procedure in the laboratory. 
